PMID- 33014110
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Effect of Moxibustion on the Serum Levels of MMP-1, MMP-3, and VEGF in Patients 
      with Rheumatoid Arthritis.
PG  - 7150605
LID - 10.1155/2020/7150605 [doi]
LID - 7150605
AB  - BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune 
      disease, which will eventually lead to joints deformity and functional damage. 
      The aim of this research is to evaluate the effect of moxibustion on the serum 
      indicators related to bone and cartilage metabolism, matrix metalloproteinase 1 
      (MMP-1), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth 
      factor (VEGF) in patients with RA and to explore the mechanism of moxibustion in 
      the treatment of RA. METHODS: We recruited 70 RA patients who met the inclusion 
      criteria, and they were randomly divided into two groups, a treatment group and a 
      control group in equal ratio. The control group took methotrexate, folate, or 
      leflunomide orally, while the treatment group received methotrexate, folate, or 
      leflunomide orally and moxibustion at ST36 (Zusanli), BL23 (Shen shu), and Ashi 
      points. We compared the clinical symptoms, RA serological disease markers and 
      serum contents of interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), MMP-1, 
      MMP-3, and VEGF of RA patients before and after treatment. RESULTS: (1) The 
      clinical symptoms and RA serological disease markers of the two groups improved 
      after treatment (P < 0.05), while the clinical symptoms of the treatment group 
      were significantly improved in comparison with the control group (P < 0.05). (2) 
      The levels of IL-1beta, TNF-alpha, and VEGF decreased in both groups after treatment 
      (P < 0.05), but the treatment group was significantly decreased compared with the 
      control group (P < 0.05). (3) There were significant differences in MMP-1 and 
      MMP-3 contents after treatment in the treatment group (P < 0.05, P < 0.05), while 
      there were no significant differences in the control group (P > 0.05, P > 0.05). 
      Above all, the contents of IL-1beta, TNF-alpha, MMP-1, MMP-3, and VEGF in the treatment 
      group decreased more significantly than those in the control group (P < 0.05). 
      CONCLUSION: The improvement effect of moxibustion on the clinical symptoms of RA 
      patients may be related to influence on the contents of IL-1beta, TNF-alpha, MMP-1, 
      MMP-3, and VEGF, and moxibustion may play a potential role in bone protection.
CI  - Copyright (c) 2020 Zeyun Yu et al.
FAU - Yu, Zeyun
AU  - Yu Z
AD  - Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, 
      China.
FAU - Wang, Yingni
AU  - Wang Y
AD  - Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, 
      China.
FAU - Li, Yuan
AU  - Li Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 
      610075, China.
FAU - Liao, Chenxi
AU  - Liao C
AD  - Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, 
      China.
FAU - Dai, Jingyang
AU  - Dai J
AD  - Chengdu Fifth People' Hospital, Chengdu 611130, China.
FAU - Luo, Yun
AU  - Luo Y
AD  - Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, 
      China.
FAU - Hu, Yuanzhang
AU  - Hu Y
AD  - Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, 
      China.
FAU - Tao, Siyu
AU  - Tao S
AD  - Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, 
      China.
FAU - Tang, Jie
AU  - Tang J
AD  - Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, 
      China.
FAU - Chen, Guanhua
AU  - Chen G
AD  - Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, 
      China.
FAU - Wu, Ping
AU  - Wu P
AUID- ORCID: 0000-0003-4062-9447
AD  - Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7519456
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
PMCR- 2020/09/16
CRDT- 2020/10/05 06:17
PHST- 2020/03/30 00:00 [received]
PHST- 2020/08/18 00:00 [revised]
PHST- 2020/09/04 00:00 [accepted]
PHST- 2020/10/05 06:17 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
PHST- 2020/09/16 00:00 [pmc-release]
AID - 10.1155/2020/7150605 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Sep 16;2020:7150605. doi: 
      10.1155/2020/7150605. eCollection 2020.